{"id":36958,"date":"2026-06-06T09:15:20","date_gmt":"2026-06-06T03:45:20","guid":{"rendered":"https:\/\/atsixty.com\/?p=36958"},"modified":"2026-06-06T09:57:34","modified_gmt":"2026-06-06T04:27:34","slug":"rheumatology-mixed-high-yield","status":"publish","type":"post","link":"https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-mixed-high-yield\/","title":{"rendered":"Rheumatology Series: Mixed High-Yield Round"},"content":{"rendered":"\n\n\n<meta charset=\"UTF-8\">\n<meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\">\n<title>Morning Rounds \u00b7 Rheumatology Mixed High-Yield Round<\/title>\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;1,400;1,600&#038;family=Source+Serif+4:ital,wght@0,300;0,400;0,600;1,400&#038;display=swap\" rel=\"stylesheet\">\n<style>\n#rhmq07 *,#rhmq07 *::before,#rhmq07 *::after{box-sizing:border-box;margin:0;padding:0}\n#rhmq07{\n  --ter:#8B3D20;\n  --ter-light:#B85A38;\n  --ter-pale:#FDF0EB;\n  --ter-dark:#6B2D14;\n  --correct:#2D6B47;--correct-bg:#EAF6EF;--correct-border:#3A9960;\n  --wrong:#B83232;--wrong-bg:#FDF0F0;--wrong-border:#E53935;\n  --ink:#2C1810;--ink-mid:#5A3D30;--ink-soft:#9A7060;\n  --line:#E8DDD8;--cream:#FAF6F2;--warm:#FFFDF9;\n  font-family:'Source Serif 4',Georgia,serif;\n  font-size:16px;color:var(--ink);background:var(--cream);\n  line-height:1.7;padding:0 0 64px;\n}\n#rhmq07 .mr-header{background:var(--ter);color:#FFFDF9;padding:34px 24px 28px;text-align:center}\n#rhmq07 .mr-eyebrow{font-size:0.68rem;letter-spacing:0.18em;text-transform:uppercase;font-weight:600;opacity:0.65;margin-bottom:10px}\n#rhmq07 .mr-title{font-family:'Playfair Display',serif;font-size:1.75rem;font-weight:700;line-height:1.2;margin-bottom:4px}\n#rhmq07 .mr-title em{font-style:italic;font-weight:400;opacity:0.88}\n#rhmq07 .mr-subtitle{font-size:0.82rem;opacity:0.7;margin-top:8px;font-style:italic}\n#rhmq07 .mr-chips{display:flex;justify-content:center;gap:10px;margin-top:18px;flex-wrap:wrap}\n#rhmq07 .mr-chip{background:rgba(255,255,255,0.13);border:1px solid rgba(255,255,255,0.22);border-radius:20px;padding:4px 13px;font-size:0.73rem}\n#rhmq07 .mr-sentinel{height:1px}\n#rhmq07 .mr-progress{position:fixed;top:0;left:0;right:0;z-index:9999;background:var(--warm);border-bottom:1px solid var(--line);box-shadow:0 2px 12px rgba(44,24,16,0.08);padding:9px 16px;display:none}\n#rhmq07 .mr-progress.visible{display:block}\n#rhmq07 .mr-prog-inner{max-width:720px;margin:0 auto;display:flex;align-items:center;justify-content:center}\n#rhmq07 .mr-pips{display:flex;align-items:center;justify-content:center}\n#rhmq07 .mr-pip-wrap{display:flex;align-items:center}\n#rhmq07 .mr-pip-line{width:28px;height:2px;background:var(--line);transition:background 0.35s}\n#rhmq07 .mr-pip-line.done{background:var(--ter)}\n#rhmq07 .mr-pip{width:28px;height:28px;border-radius:50%;border:2px solid var(--line);background:var(--warm);display:flex;align-items:center;justify-content:center;font-size:0.63rem;font-weight:700;color:var(--ink-soft);transition:all 0.3s;flex-shrink:0}\n#rhmq07 .mr-pip.correct{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#rhmq07 .mr-pip.wrong{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#rhmq07 .mr-body{max-width:720px;margin:0 auto;padding:0 16px}\n#rhmq07 .mr-case{background:var(--warm);border:1px solid var(--line);border-left:4px solid var(--ter);border-radius:10px;margin:28px 0;overflow:hidden;box-shadow:0 1px 6px rgba(44,24,16,0.05)}\n#rhmq07 .mr-case-top{padding:16px 20px 14px;display:flex;gap:14px;align-items:flex-start}\n#rhmq07 .mr-num{font-family:'Playfair Display',serif;font-size:2.2rem;font-weight:700;color:var(--ter);opacity:0.16;line-height:1;margin-top:-2px;flex-shrink:0}\n#rhmq07 .mr-meta{flex:1}\n#rhmq07 .mr-tag-row{display:flex;align-items:center;justify-content:space-between;margin-bottom:5px}\n#rhmq07 .mr-tag{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--ter);opacity:0.8}\n#rhmq07 .mr-diff{font-size:0.61rem;font-weight:700;letter-spacing:0.10em;text-transform:uppercase;color:var(--ink-soft)}\n#rhmq07 .mr-stem{font-size:0.94rem;color:var(--ink);line-height:1.72}\n#rhmq07 .mr-stem strong{font-weight:600}\n#rhmq07 .mr-stem em{font-style:italic}\n#rhmq07 .mr-rule{height:1px;background:var(--line);margin:0 20px}\n#rhmq07 .mr-opts{padding:12px 20px 16px;display:flex;flex-direction:column;gap:8px}\n#rhmq07 .mr-opt{display:flex;align-items:flex-start;gap:11px;padding:10px 14px;border:1.5px solid var(--line);border-radius:8px;cursor:pointer;background:var(--warm);transition:border-color 0.15s,background 0.15s;-webkit-tap-highlight-color:transparent}\n#rhmq07 .mr-opt:hover{border-color:var(--ter);background:var(--ter-pale)}\n#rhmq07 .mr-opt.locked{cursor:default}\n#rhmq07 .mr-opt.locked:hover{border-color:var(--line);background:var(--warm)}\n#rhmq07 .mr-opt.correct{border-color:var(--correct-border);background:var(--correct-bg);cursor:default}\n#rhmq07 .mr-opt.correct:hover{border-color:var(--correct-border);background:var(--correct-bg)}\n#rhmq07 .mr-opt.wrong{border-color:var(--wrong-border);background:var(--wrong-bg);cursor:default}\n#rhmq07 .mr-opt.wrong:hover{border-color:var(--wrong-border);background:var(--wrong-bg)}\n#rhmq07 .mr-opt.dimmed{opacity:0.35;cursor:default}\n#rhmq07 .mr-opt.dimmed:hover{border-color:var(--line);background:var(--warm)}\n#rhmq07 .mr-ltr{flex-shrink:0;width:20px;height:20px;border-radius:50%;border:1.5px solid var(--line);display:flex;align-items:center;justify-content:center;font-size:0.62rem;font-weight:700;color:var(--ink-soft);margin-top:2px;transition:all 0.15s}\n#rhmq07 .mr-opt.correct .mr-ltr{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#rhmq07 .mr-opt.wrong .mr-ltr{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#rhmq07 .mr-opt-text{font-size:0.9rem;color:var(--ink-mid);line-height:1.58}\n#rhmq07 .mr-opt.correct .mr-opt-text{color:var(--correct);font-weight:600}\n#rhmq07 .mr-opt.wrong .mr-opt-text{color:var(--wrong)}\n#rhmq07 .mr-exp{display:none;border-top:1px solid #c8e0d8;background:linear-gradient(180deg,#edf7f4 0%,#f4faf8 100%);padding:13px 20px 15px}\n#rhmq07 .mr-exp-lbl{font-size:0.61rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;color:var(--correct);margin-bottom:6px}\n#rhmq07 .mr-exp-text{font-size:0.86rem;color:#1c4a3a;line-height:1.68}\n#rhmq07 .mr-exp-text strong{font-weight:600}\n#rhmq07 .mr-exp-text em{font-style:italic}\n#rhmq07 .mr-exp-extra{margin-top:11px;padding-top:10px;border-top:1px dashed #9ACCC4;font-size:0.84rem;color:#1c4a3a;line-height:1.66}\n#rhmq07 .mr-exp-extra-lbl{font-size:0.59rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;color:var(--ter);margin-bottom:4px;display:block}\n#rhmq07 .mr-exp-extra strong{font-weight:600}\n#rhmq07 .mr-exp-extra em{font-style:italic}\n#rhmq07 .mr-img-wrap{margin-top:14px;background:var(--warm);border:1px solid var(--line);border-radius:8px;padding:14px;text-align:center}\n#rhmq07 .mr-img-wrap figcaption{font-size:0.73rem;color:var(--ink-soft);font-style:italic;margin-top:8px;line-height:1.4}\n#rhmq07 .mr-submit-wrap{text-align:center;padding:28px 16px 8px}\n#rhmq07 .mr-btn{background:var(--ter);color:#FFFDF9;border:none;border-radius:8px;padding:13px 44px;font-family:'Playfair Display',serif;font-size:1rem;font-weight:700;cursor:pointer;box-shadow:0 2px 8px rgba(139,61,32,0.28)}\n#rhmq07 .mr-btn:hover{background:var(--ter-dark)}\n#rhmq07 .mr-score{display:none;background:var(--warm);border:1px solid var(--line);border-top:4px solid var(--ter);border-radius:10px;margin:24px 0 0;box-shadow:0 2px 12px rgba(44,24,16,0.08);overflow:hidden}\n#rhmq07 .mr-score-in{padding:28px 24px;text-align:center}\n#rhmq07 .mr-score-ey{font-size:0.66rem;letter-spacing:0.14em;text-transform:uppercase;color:var(--ink-soft);margin-bottom:12px;font-weight:600}\n#rhmq07 .mr-ring{width:98px;height:98px;border-radius:50%;background:conic-gradient(var(--ter) 0%,var(--line) 0%);display:flex;align-items:center;justify-content:center;margin:0 auto 16px;position:relative}\n#rhmq07 .mr-ring::before{content:'';position:absolute;width:76px;height:76px;border-radius:50%;background:var(--warm)}\n#rhmq07 .mr-ring-in{position:relative;display:flex;flex-direction:column;align-items:center;line-height:1.2}\n#rhmq07 .mr-ring-pct{font-family:'Playfair Display',serif;font-size:1.3rem;font-weight:700;color:var(--ter)}\n#rhmq07 .mr-ring-sub{font-size:0.54rem;color:var(--ink-soft);text-transform:uppercase;letter-spacing:0.06em}\n#rhmq07 .mr-score-title{font-family:'Playfair Display',serif;font-size:1.15rem;font-weight:700;color:var(--ink);margin-bottom:4px}\n#rhmq07 .mr-score-net{font-size:0.9rem;color:var(--ter);font-weight:600;margin-bottom:4px}\n#rhmq07 .mr-verdict{font-size:0.83rem;color:var(--ink-soft);font-style:italic;margin-bottom:18px;padding:0 12px}\n#rhmq07 .mr-bands{display:flex;justify-content:center;gap:10px;flex-wrap:wrap}\n#rhmq07 .mr-band{padding:5px 13px;border-radius:16px;font-size:0.78rem;font-weight:600}\n#rhmq07 .mr-band-c{background:var(--correct-bg);color:var(--correct)}\n#rhmq07 .mr-band-w{background:var(--wrong-bg);color:var(--wrong)}\n#rhmq07 .mr-band-s{background:var(--ter-pale);color:var(--ter)}\n#rhmq07 .mr-retry{display:block;margin:18px auto 4px;background:transparent;border:2px solid var(--ter);color:var(--ter);border-radius:8px;padding:9px 28px;font-family:'Playfair Display',serif;font-size:0.92rem;font-weight:700;cursor:pointer}\n#rhmq07 .mr-retry:hover{background:var(--ter);color:#FFFDF9}\n@media(max-width:480px){#rhmq07 .mr-title{font-size:1.4rem}#rhmq07 .mr-num{font-size:1.7rem}#rhmq07 .mr-stem{font-size:0.9rem}#rhmq07 .mr-opt-text{font-size:0.86rem}}\n<\/style>\n\n<!-- Autoantibody master summary SVG for Q5 debrief -->\n<div id=\"rhmq07-img1\" style=\"display:none\">\n  <figure class=\"mr-img-wrap\">\n    <svg viewBox=\"0 0 540 210\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" style=\"width:100%;max-width:540px;display:block;margin:0 auto\">\n      <rect x=\"0\" y=\"0\" width=\"540\" height=\"210\" rx=\"8\" fill=\"#F4F8F6\"\/>\n      <!-- Header row -->\n      <rect x=\"4\" y=\"4\" width=\"170\" height=\"18\" rx=\"3\" fill=\"#2C1810\" opacity=\"0.75\"\/>\n      <text x=\"89\" y=\"16\" text-anchor=\"middle\" fill=\"#fff\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">Antibody<\/text>\n      <rect x=\"178\" y=\"4\" width=\"175\" height=\"18\" rx=\"3\" fill=\"#2C1810\" opacity=\"0.75\"\/>\n      <text x=\"265\" y=\"16\" text-anchor=\"middle\" fill=\"#fff\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">Disease<\/text>\n      <rect x=\"357\" y=\"4\" width=\"178\" height=\"18\" rx=\"3\" fill=\"#2C1810\" opacity=\"0.75\"\/>\n      <text x=\"446\" y=\"16\" text-anchor=\"middle\" fill=\"#fff\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">Key Point<\/text>\n      <!-- Rows -->\n      <text x=\"8\" y=\"36\" fill=\"#8B3D20\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">Anti-dsDNA<\/text>\n      <text x=\"182\" y=\"36\" fill=\"#3D5A80\" font-size=\"8.5\" font-family=\"Georgia,serif\">SLE (specific)<\/text>\n      <text x=\"361\" y=\"36\" fill=\"#5A3D30\" font-size=\"8.5\" font-family=\"Georgia,serif\">Titres track disease activity<\/text>\n\n      <text x=\"8\" y=\"52\" fill=\"#8B3D20\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">Anti-Sm<\/text>\n      <text x=\"182\" y=\"52\" fill=\"#3D5A80\" font-size=\"8.5\" font-family=\"Georgia,serif\">SLE (most specific)<\/text>\n      <text x=\"361\" y=\"52\" fill=\"#5A3D30\" font-size=\"8.5\" font-family=\"Georgia,serif\">Does not track activity<\/text>\n\n      <text x=\"8\" y=\"68\" fill=\"#8B3D20\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">Anti-histone<\/text>\n      <text x=\"182\" y=\"68\" fill=\"#3D5A80\" font-size=\"8.5\" font-family=\"Georgia,serif\">Drug-induced lupus<\/text>\n      <text x=\"361\" y=\"68\" fill=\"#5A3D30\" font-size=\"8.5\" font-family=\"Georgia,serif\">Anti-dsDNA absent in DIL<\/text>\n\n      <text x=\"8\" y=\"84\" fill=\"#8B3D20\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">Anti-SSA (Ro)<\/text>\n      <text x=\"182\" y=\"84\" fill=\"#3D5A80\" font-size=\"8.5\" font-family=\"Georgia,serif\">Sjogren's; SLE<\/text>\n      <text x=\"361\" y=\"84\" fill=\"#5A3D30\" font-size=\"8.5\" font-family=\"Georgia,serif\">Neonatal lupus; CHB<\/text>\n\n      <text x=\"8\" y=\"100\" fill=\"#8B3D20\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">Anti-SSB (La)<\/text>\n      <text x=\"182\" y=\"100\" fill=\"#3D5A80\" font-size=\"8.5\" font-family=\"Georgia,serif\">Sjogren's (more specific)<\/text>\n      <text x=\"361\" y=\"100\" fill=\"#5A3D30\" font-size=\"8.5\" font-family=\"Georgia,serif\">Usually with anti-SSA<\/text>\n\n      <text x=\"8\" y=\"116\" fill=\"#8B3D20\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">Anti-centromere<\/text>\n      <text x=\"182\" y=\"116\" fill=\"#3D5A80\" font-size=\"8.5\" font-family=\"Georgia,serif\">Limited SSc (CREST)<\/text>\n      <text x=\"361\" y=\"116\" fill=\"#5A3D30\" font-size=\"8.5\" font-family=\"Georgia,serif\">PAH; late ILD<\/text>\n\n      <text x=\"8\" y=\"132\" fill=\"#8B3D20\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">Anti-Scl-70<\/text>\n      <text x=\"182\" y=\"132\" fill=\"#3D5A80\" font-size=\"8.5\" font-family=\"Georgia,serif\">Diffuse SSc<\/text>\n      <text x=\"361\" y=\"132\" fill=\"#5A3D30\" font-size=\"8.5\" font-family=\"Georgia,serif\">Early severe ILD<\/text>\n\n      <text x=\"8\" y=\"148\" fill=\"#8B3D20\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">Anti-Jo-1<\/text>\n      <text x=\"182\" y=\"148\" fill=\"#3D5A80\" font-size=\"8.5\" font-family=\"Georgia,serif\">Antisynthetase syndrome<\/text>\n      <text x=\"361\" y=\"148\" fill=\"#5A3D30\" font-size=\"8.5\" font-family=\"Georgia,serif\">ILD + myositis + arthritis<\/text>\n\n      <text x=\"8\" y=\"164\" fill=\"#8B3D20\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">Anti-U1-RNP<\/text>\n      <text x=\"182\" y=\"164\" fill=\"#3D5A80\" font-size=\"8.5\" font-family=\"Georgia,serif\">MCTD (defining)<\/text>\n      <text x=\"361\" y=\"164\" fill=\"#5A3D30\" font-size=\"8.5\" font-family=\"Georgia,serif\">High titre; PAH risk<\/text>\n\n      <text x=\"8\" y=\"180\" fill=\"#8B3D20\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">c-ANCA \/ PR3<\/text>\n      <text x=\"182\" y=\"180\" fill=\"#3D5A80\" font-size=\"8.5\" font-family=\"Georgia,serif\">GPA (Wegener's)<\/text>\n      <text x=\"361\" y=\"180\" fill=\"#5A3D30\" font-size=\"8.5\" font-family=\"Georgia,serif\">ENT + lung + kidney<\/text>\n\n      <text x=\"8\" y=\"196\" fill=\"#8B3D20\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">p-ANCA \/ MPO<\/text>\n      <text x=\"182\" y=\"196\" fill=\"#3D5A80\" font-size=\"8.5\" font-family=\"Georgia,serif\">MPA; EGPA<\/text>\n      <text x=\"361\" y=\"196\" fill=\"#5A3D30\" font-size=\"8.5\" font-family=\"Georgia,serif\">EGPA: asthma + eosinophilia<\/text>\n\n      <!-- Horizontal dividers -->\n      <line x1=\"4\" y1=\"22\" x2=\"536\" y2=\"22\" stroke=\"#C8D8D4\" stroke-width=\"0.8\"\/>\n      <line x1=\"4\" y1=\"38\" x2=\"536\" y2=\"38\" stroke=\"#E8DDD8\" stroke-width=\"0.5\"\/>\n      <line x1=\"4\" y1=\"54\" x2=\"536\" y2=\"54\" stroke=\"#E8DDD8\" stroke-width=\"0.5\"\/>\n      <line x1=\"4\" y1=\"70\" x2=\"536\" y2=\"70\" stroke=\"#E8DDD8\" stroke-width=\"0.5\"\/>\n      <line x1=\"4\" y1=\"86\" x2=\"536\" y2=\"86\" stroke=\"#E8DDD8\" stroke-width=\"0.5\"\/>\n      <line x1=\"4\" y1=\"102\" x2=\"536\" y2=\"102\" stroke=\"#E8DDD8\" stroke-width=\"0.5\"\/>\n      <line x1=\"4\" y1=\"118\" x2=\"536\" y2=\"118\" stroke=\"#E8DDD8\" stroke-width=\"0.5\"\/>\n      <line x1=\"4\" y1=\"134\" x2=\"536\" y2=\"134\" stroke=\"#E8DDD8\" stroke-width=\"0.5\"\/>\n      <line x1=\"4\" y1=\"150\" x2=\"536\" y2=\"150\" stroke=\"#E8DDD8\" stroke-width=\"0.5\"\/>\n      <line x1=\"4\" y1=\"166\" x2=\"536\" y2=\"166\" stroke=\"#E8DDD8\" stroke-width=\"0.5\"\/>\n      <line x1=\"4\" y1=\"182\" x2=\"536\" y2=\"182\" stroke=\"#E8DDD8\" stroke-width=\"0.5\"\/>\n      <!-- Vertical dividers -->\n      <line x1=\"175\" y1=\"4\" x2=\"175\" y2=\"206\" stroke=\"#C8D8D4\" stroke-width=\"0.8\"\/>\n      <line x1=\"354\" y1=\"4\" x2=\"354\" y2=\"206\" stroke=\"#C8D8D4\" stroke-width=\"0.8\"\/>\n    <\/svg>\n    <figcaption>\n      High-yield autoantibody master table for NEET-PG and UPSC CMS. Commit the <strong>disease-specific antibodies<\/strong> first: anti-dsDNA and anti-Sm (SLE); anti-centromere (lcSSc); anti-Scl-70 (dcSSc); anti-Jo-1 (antisynthetase); anti-U1-RNP (MCTD); c-ANCA\/PR3 (GPA); p-ANCA\/MPO (MPA, EGPA).\n    <\/figcaption>\n  <\/figure>\n<\/div>\n\n<div id=\"rhmq07\">\n\n  <div class=\"mr-header\">\n    <div class=\"mr-eyebrow\">Morning Rounds &middot; Rheumatology Series &middot; Round 07<\/div>\n    <div class=\"mr-title\">\n      Mixed High-Yield Round<br><em>Exam Simulation<\/em>\n    <\/div>\n    <div class=\"mr-subtitle\">Cross-cutting cases drawn from the full rheumatology spectrum &middot; NEET-PG and UPSC CMS pattern<\/div>\n    <div class=\"mr-chips\">\n      <span class=\"mr-chip\">5 Cases<\/span>\n      <span class=\"mr-chip\">+4 \/ &minus;1 scoring<\/span>\n      <span class=\"mr-chip\">Options reshuffled<\/span>\n    <\/div>\n  <\/div>\n\n  <div class=\"mr-sentinel\" id=\"rhmq07-sentinel\"><\/div>\n\n  <div class=\"mr-progress\" id=\"rhmq07-progress\">\n    <div class=\"mr-prog-inner\">\n      <div class=\"mr-pips\" id=\"rhmq07-pips\"><\/div>\n    <\/div>\n  <\/div>\n\n  <div class=\"mr-body\">\n    <div id=\"rhmq07-cases\"><\/div>\n    <div class=\"mr-submit-wrap\">\n      <button class=\"mr-btn\" id=\"rhmq07-submit\">Submit for Debrief<\/button>\n    <\/div>\n    <div class=\"mr-score\" id=\"rhmq07-score\">\n      <div class=\"mr-score-in\">\n        <div class=\"mr-score-ey\">Round Complete<\/div>\n        <div class=\"mr-ring\" id=\"rhmq07-ring\">\n          <div class=\"mr-ring-in\">\n            <span class=\"mr-ring-pct\" id=\"rhmq07-pct\">0%<\/span>\n            <span class=\"mr-ring-sub\">net<\/span>\n          <\/div>\n        <\/div>\n        <div class=\"mr-score-title\">Your Debrief<\/div>\n        <div class=\"mr-score-net\" id=\"rhmq07-net\"><\/div>\n        <div class=\"mr-verdict\" id=\"rhmq07-verdict\"><\/div>\n        <div class=\"mr-bands\">\n          <span class=\"mr-band mr-band-c\" id=\"rhmq07-ct-c\"><\/span>\n          <span class=\"mr-band mr-band-w\" id=\"rhmq07-ct-w\"><\/span>\n          <span class=\"mr-band mr-band-s\" id=\"rhmq07-ct-s\"><\/span>\n        <\/div>\n        <button class=\"mr-retry\" id=\"rhmq07-retry\">&#8635; New Round<\/button>\n      <\/div>\n    <\/div>\n  <\/div>\n\n<\/div><!-- end #rhmq07 -->\n\n<script>\n(function () {\n  'use strict';\n\n  var NS    = 'rhmq07';\n  var TOTAL = 5;\n  var MAX   = 20;\n  var LTRS  = ['A','B','C','D'];\n\n  var QS = [\n\n    \/* ---- Q1 : RA \u2014 Felty's Syndrome (cross-cutting RA + haematology) ---- *\/\n    {\n      id:   1,\n      diff: 'Medium',\n      tag:  'Rheumatoid Arthritis &mdash; Felty\\'s Syndrome',\n      stem: 'A <strong>58-year-old woman<\/strong> with a <strong>22-year history of seropositive RA<\/strong> (high-titre RF and anti-CCP) presents with recurrent bacterial infections over the past 18 months. Examination reveals <strong>splenomegaly<\/strong>, very little active synovitis despite minimal DMARD use, and <strong>bilateral leg ulcers<\/strong>. Full blood count shows: Hb 9.8 g\/dL (normochromic normocytic), WBC <strong>1.8 &times; 10&sup9;\/L<\/strong> with <strong>neutrophil count 0.7 &times; 10&sup9;\/L<\/strong>, platelets 112 &times; 10&sup9;\/L. ANA is positive; anti-dsDNA negative. Which combination of diagnosis, mechanism, and management is <em>most accurate<\/em>?',\n      correct: 'Felty\\'s syndrome (RA + splenomegaly + neutropaenia); neutropaenia results from splenic sequestration and anti-neutrophil antibodies; methotrexate and G-CSF are used for severe neutropaenia with recurrent infection; splenectomy is reserved for refractory cases',\n      opts: [\n        'Felty\\'s syndrome (RA + splenomegaly + neutropaenia); neutropaenia results from splenic sequestration and anti-neutrophil antibodies; methotrexate and G-CSF are used for severe neutropaenia with recurrent infection; splenectomy is reserved for refractory cases',\n        'This is methotrexate-induced pancytopaenia; the splenomegaly is reactive from chronic infection; methotrexate must be stopped immediately and folinic acid rescue given; the neutropaenia will resolve within 7&ndash;10 days of drug withdrawal',\n        'Large granular lymphocyte (LGL) leukaemia should be excluded first as it mimics Felty\\'s syndrome; however, LGL leukaemia is treated identically to Felty\\'s with splenectomy as first-line treatment before any DMARD therapy is attempted',\n        'The positive ANA with neutropaenia and splenomegaly confirms a transition from RA to SLE (rhupus); anti-dsDNA should be retested and hydroxychloroquine started immediately as it covers both conditions without the infection risk of methotrexate'\n      ],\n      exp:  '<strong>Felty\\'s syndrome<\/strong> is the triad of: <strong>seropositive RA + splenomegaly + neutropaenia<\/strong> (neutrophil count &lt;2.0 &times; 10&sup9;\/L). It occurs in &lt;1% of RA patients, typically after &gt;10 years of severe seropositive disease. Paradoxically, joint disease may be quiescent while extra-articular features dominate. <strong>Mechanisms of neutropaenia<\/strong>: (1) splenic sequestration and destruction; (2) anti-neutrophil antibodies; (3) bone marrow suppression by immune complexes. Complications: recurrent bacterial infections (the primary clinical concern), leg ulcers (from neutrophil-mediated vasculitis), and lymphoma risk (raised, as in Sjogren\\'s). <strong>Management<\/strong>: treat underlying RA aggressively with DMARDs (methotrexate, hydroxychloroquine); G-CSF for severe neutropaenia with active infection; splenectomy for refractory cases. <strong>LGL leukaemia<\/strong> must be excluded (blood film + flow cytometry) as it produces an identical clinical picture but requires different treatment (methotrexate or cyclophosphamide, not splenectomy first).',\n      extra: '<strong>Extra-articular features of RA<\/strong> &mdash; high-yield summary:<br>Pulmonary: ILD (UIP\/NSIP pattern); pleural effusion (exudate, low glucose, low complement); Caplan\\'s syndrome (ILD + pneumoconiosis); bronchiectasis.<br>Cardiac: pericarditis (most common cardiac manifestation); accelerated atherosclerosis; rarely myocarditis.<br>Ocular: episcleritis (benign, self-limiting); scleritis (painful, sight-threatening, indicates active systemic disease); keratoconjunctivitis sicca (secondary Sjogren\\'s in 30%).<br>Haematological: Felty\\'s syndrome; anaemia of chronic disease; AIHA (rare).<br>Neurological: cervical myelopathy from C1&ndash;C2 atlantoaxial subluxation (a pre-operative and pre-anaesthetic emergency &mdash; always check lateral cervical spine X-ray in flexion before intubating an RA patient); peripheral neuropathy; mononeuritis multiplex.<br>Vasculitis: digital infarcts, leg ulcers, mononeuritis multiplex &mdash; indicates severe systemic disease; associated with high RF titre.',\n      imgId: null\n    },\n\n    \/* ---- Q2 : Hydroxychloroquine \u2014 Mechanism & Toxicity ---- *\/\n    {\n      id:   2,\n      diff: 'Medium',\n      tag:  'Rheumatology Pharmacology &mdash; Hydroxychloroquine',\n      stem: 'A <strong>34-year-old woman<\/strong> with SLE has been on <strong>hydroxychloroquine (HCQ) 400 mg\/day<\/strong> for <strong>six years<\/strong>. Her disease has been well controlled. She now presents for routine review. Her weight is 52 kg (ideal body weight). Her ophthalmologist flags that her <strong>annual retinal screening<\/strong> has shown early bull\\'s-eye maculopathy changes on fundal examination. Renal function and urine protein are normal. She asks whether she needs to continue HCQ given that her SLE is in remission. Which combination of statements is <em>most accurate<\/em>?',\n      correct: 'HCQ should not be stopped even in remission as it reduces SLE flare rates, organ damage accrual, and mortality; retinal toxicity risk increases after 5 years of use and is dose-dependent; the recommended maximum dose is 5 mg\/kg\/day of actual body weight; retinal changes are an indication to stop HCQ',\n      opts: [\n        'HCQ should not be stopped even in remission as it reduces SLE flare rates, organ damage accrual, and mortality; retinal toxicity risk increases after 5 years of use and is dose-dependent; the recommended maximum dose is 5 mg\/kg\/day of actual body weight; retinal changes are an indication to stop HCQ',\n        'HCQ can be safely stopped once SLE has been in clinical remission for 12 months as the anti-inflammatory effect persists for 6&ndash;12 months after discontinuation; retinal bull\\'s-eye maculopathy is reversible if HCQ is stopped early and vision will fully recover',\n        'The maximum safe dose of HCQ is 6.5 mg\/kg\/day of ideal body weight; since this patient weighs 52 kg her dose of 400 mg\/day is within the safe range and retinal screening findings are not an indication to modify her treatment',\n        'HCQ retinal toxicity only occurs in patients with pre-existing renal impairment; since her renal function is normal the maculopathy changes are coincidental and her HCQ dose should be increased to 600 mg\/day to maintain disease suppression'\n      ],\n      exp:  '<strong>Hydroxychloroquine<\/strong> is the cornerstone of SLE management &mdash; it should be continued <em>indefinitely<\/em> in virtually all SLE patients regardless of disease activity. Its benefits: reduces flare frequency by ~50%; reduces organ damage accrual; lowers thrombosis risk (especially relevant in APS overlap); reduces mortality; safe in pregnancy. <strong>Retinal toxicity<\/strong>: the principal long-term risk. Risk is low (&lt;1%) in the first 5 years but rises to 2&ndash;4% at 10 years and higher beyond. Risk factors: high dose, long duration, renal impairment, tamoxifen co-prescription, pre-existing macular disease. <strong>Safe dosing: &le;5 mg\/kg\/day of actual body weight<\/strong> (revised downward from the older 6.5 mg\/kg ideal body weight guideline &mdash; an exam trap). At 52 kg, maximum safe dose = 260 mg\/day; 400 mg\/day represents significant overdosing. <strong>Bull\\'s-eye maculopathy<\/strong> on fundoscopy indicates established toxicity &mdash; HCQ must be <strong>stopped<\/strong>. Retinal damage is largely <em>irreversible<\/em> &mdash; vision loss may continue to progress even after stopping.',\n      extra: '<strong>Annual retinal screening protocol (AAO 2016 guidelines)<\/strong>: baseline examination at start of HCQ; annual screening from year 5 onwards (or earlier if risk factors present). Preferred modality: <strong>automated visual field testing + spectral-domain OCT<\/strong> (most sensitive for early parafoveal damage before fundoscopic changes appear). Fundoscopy alone is inadequate for early detection. <strong>HCQ mechanism of action<\/strong>: raises lysosomal pH, inhibiting TLR (Toll-like receptor) signalling by blocking nucleic acid recognition; inhibits antigen presentation; reduces pro-inflammatory cytokine release (IL-1, IL-6, TNF-&alpha;). This is why it reduces flares but does not treat acute severe SLE &mdash; it is a disease modifier, not an immunosuppressant in the conventional sense. <strong>HCQ in pregnancy<\/strong>: safe throughout all trimesters; stopping HCQ in pregnancy increases lupus flare risk and is not recommended.',\n      imgId: null\n    },\n\n    \/* ---- Q3 : Raynaud's \u2014 Primary vs Secondary ---- *\/\n    {\n      id:   3,\n      diff: 'Medium',\n      tag:  'Raynaud\\'s Phenomenon &mdash; Primary vs Secondary',\n      stem: 'Two patients present with <strong>episodic colour change of the fingers<\/strong> (white &rarr; blue &rarr; red) triggered by cold exposure. <strong>Patient A<\/strong> is a <strong>19-year-old woman<\/strong> with symmetric involvement of all fingers bilaterally, no digital ulcers, no nail-fold changes, ANA negative, and normal ESR. <strong>Patient B<\/strong> is a <strong>44-year-old woman<\/strong> with asymmetric involvement, one digital ulcer on the right index finger, <strong>dilated and distorted nail-fold capillaries on dermoscopy<\/strong>, ANA positive (1:160, speckled), anti-Scl-70 weakly positive, and ESR 44 mm\/hr. Which statement most accurately distinguishes these two patients and guides next steps?',\n      correct: 'Patient A has primary Raynaud\\'s (benign, no underlying CTD); Patient B has secondary Raynaud\\'s in early systemic sclerosis; nail-fold capillaroscopy showing giant capillaries and avascular areas is the investigation that best predicts progression to a defined CTD',\n      opts: [\n        'Patient A has primary Raynaud\\'s (benign, no underlying CTD); Patient B has secondary Raynaud\\'s in early systemic sclerosis; nail-fold capillaroscopy showing giant capillaries and avascular areas is the investigation that best predicts progression to a defined CTD',\n        'Both patients have primary Raynaud\\'s phenomenon; ANA positivity and mildly elevated ESR are non-specific findings and do not indicate CTD without skin thickening; anti-Scl-70 positivity is only significant above a titre of 1:320',\n        'Patient B\\'s digital ulcer confirms critical digital ischaemia requiring emergency IV iloprost; nail-fold capillaroscopy is a research tool not recommended in clinical practice; all Raynaud\\'s patients with ANA positivity should undergo renal biopsy to exclude early scleroderma nephropathy',\n        'The triple colour change (white-blue-red) is pathognomonic of secondary Raynaud\\'s and excludes primary disease in both patients; calcium channel blockers are contraindicated in primary Raynaud\\'s as they cause paradoxical vasoconstriction in the absence of an underlying CTD'\n      ],\n      exp:  '<strong>Primary Raynaud\\'s phenomenon (PRP)<\/strong>: young women; symmetric; no digital ulcers or tissue loss; normal nail-fold capillaries; ANA negative; ESR normal; no evolution to CTD. <strong>Secondary Raynaud\\'s phenomenon (SRP)<\/strong>: older age of onset; asymmetric; digital ulcers; abnormal nail-fold capillaroscopy; positive ANA or specific antibodies; elevated inflammatory markers. <strong>Nail-fold capillaroscopy<\/strong> is the single most useful investigation to distinguish primary from secondary Raynaud\\'s and to predict CTD development. The <strong>scleroderma pattern<\/strong> (giant capillaries, haemorrhages, avascular areas, capillary loss) predicts evolution to SSc with high sensitivity and specificity. Patient B has early SSc: anti-Scl-70, abnormal capillaroscopy, digital ulcer. <strong>Treatment<\/strong>: lifestyle (gloves, heated clothing); <strong>calcium channel blockers<\/strong> (nifedipine, amlodipine) are first-line for both primary and secondary RP; PDE-5 inhibitors (sildenafil) for refractory; IV iloprost for critical ischaemia\/digital ulcers.',\n      extra: '<strong>LeRoy &amp; Medsger criteria for very early SSc<\/strong>: Raynaud\\'s phenomenon PLUS either (1) SSc-specific antibodies (anti-centromere, anti-Scl-70, anti-RNA pol III) OR (2) scleroderma pattern on nail-fold capillaroscopy. Patients meeting these criteria have a high probability of evolving to definite SSc even before skin thickening appears &mdash; they require annual surveillance. <strong>Causes of secondary Raynaud\\'s<\/strong>: CTDs (SSc most common, SLE, MCTD, Sjogren\\'s, inflammatory myopathy); obstructive (atherosclerosis, thoracic outlet syndrome); drugs (beta-blockers, ergotamine, bleomycin, ciclosporin, amphetamines); occupational (vibration white finger); haematological (cryoglobulinaemia, polycythaemia, cold agglutinins). <strong>ABCDE of digital ulcer management in SSc<\/strong>: Antibiotics (if infected); Bosentan (endothelin receptor antagonist, reduces new ulcer formation); CCB optimisation; Digital sympathectomy (refractory); Endothelin antagonist (bosentan) or PDE-5 inhibitor.',\n      imgId: null\n    },\n\n    \/* ---- Q4 : Methotrexate \u2014 Mechanisms & Monitoring ---- *\/\n    {\n      id:   4,\n      diff: 'Hard',\n      tag:  'Rheumatology Pharmacology &mdash; Methotrexate',\n      stem: 'A <strong>47-year-old man<\/strong> with RA has been on <strong>methotrexate (MTX) 20 mg\/week<\/strong> and <strong>folic acid 5 mg\/week<\/strong> for three years with good disease control. He now presents with <strong>progressive dyspnoea over 6 weeks<\/strong>, a <strong>dry cough<\/strong>, and mild fever. He is a non-smoker. O&sup2; saturation is 93% on air. CXR shows bilateral interstitial infiltrates. His RA joint disease remains well controlled. CRP is 18 mg\/L. HRCT chest shows bilateral ground-glass opacities with a predominant upper-lobe distribution and no honeycombing. BAL shows <strong>lymphocytosis (CD4+ predominant)<\/strong>. Which of the following statements best characterises this complication and its management?',\n      correct: 'This is methotrexate pneumonitis (hypersensitivity pneumonitis); it is idiosyncratic, not dose-dependent, and can occur at any time; MTX must be stopped immediately; corticosteroids are used for moderate-to-severe disease; MTX should not be restarted after confirmed pneumonitis',\n      opts: [\n        'This is methotrexate pneumonitis (hypersensitivity pneumonitis); it is idiosyncratic, not dose-dependent, and can occur at any time; MTX must be stopped immediately; corticosteroids are used for moderate-to-severe disease; MTX should not be restarted after confirmed pneumonitis',\n        'This is RA-associated ILD (RA-ILD) unrelated to methotrexate; the bilateral ground-glass opacities with upper-lobe predominance are typical of the UIP pattern seen in RA-ILD; MTX should be continued and anti-fibrotic therapy with nintedanib started immediately',\n        'MTX pneumonitis only occurs when folic acid supplementation is omitted; since this patient is on folic acid 5 mg\/week the pulmonary infiltrates represent opportunistic Pneumocystis jirovecii pneumonia (PCP); co-trimoxazole should be started empirically and MTX dose halved',\n        'The dose-dependent nature of MTX toxicity means pneumonitis only occurs at doses above 25 mg\/week; at 20 mg\/week the lung infiltrates are more likely to represent a community-acquired pneumonia; antibiotics should be given and MTX continued without interruption'\n      ],\n      exp:  '<strong>Methotrexate pneumonitis<\/strong> is a <strong>hypersensitivity reaction<\/strong>, not a dose-dependent toxicity &mdash; it can occur at any dose and at any time during treatment (weeks to years). It is <em>not prevented by folic acid supplementation<\/em> (folic acid prevents haematological and mucosal toxicity but not pneumonitis). Clinical features: subacute dyspnoea, dry cough, fever, bilateral interstitial infiltrates on CXR\/HRCT. BAL characteristically shows <strong>CD4+ lymphocytosis<\/strong> (reflecting hypersensitivity). HRCT may show ground-glass opacities, often with upper-lobe predominance &mdash; distinct from the basal-predominant UIP pattern of RA-ILD. <strong>Management<\/strong>: stop MTX immediately; corticosteroids (prednisolone 1 mg\/kg\/day) for moderate-to-severe disease; <strong>MTX should not be restarted<\/strong> after confirmed pneumonitis (risk of recurrence with potentially fatal outcome). Switch to an alternative DMARD (leflunomide, sulfasalazine, or biologic).',\n      extra: '<strong>MTX monitoring protocol (BSR guidelines)<\/strong>: FBC + LFTs before starting; monthly for 3 months, then every 3 months thereafter. <strong>Stop MTX if<\/strong>: WBC &lt;3.5 &times; 10&sup9;\/L; neutrophils &lt;2 &times; 10&sup9;\/L; platelets &lt;150 &times; 10&sup9;\/L; ALT\/AST &gt;3&times; ULN (persistent); new respiratory symptoms. <strong>Folic acid<\/strong> reduces mucosal toxicity (oral ulcers), GI side effects, and haematological toxicity by replenishing the folate pool depleted by MTX&rsquo;s DHFR inhibition. It does NOT reduce efficacy in RA (a common misconception). <strong>MTX mechanism in RA<\/strong>: at low doses used in RA, the primary mechanism is <em>adenosine release<\/em> (anti-inflammatory) rather than pure DHFR inhibition (which is the cytotoxic mechanism at chemotherapy doses). <strong>Leucovorin (folinic acid)<\/strong>: used for MTX toxicity rescue and overdose &mdash; it bypasses DHFR inhibition. Do not confuse with folic acid supplementation.',\n      imgId: null\n    },\n\n    \/* ---- Q5 : Integrated Autoantibody Case ---- *\/\n    {\n      id:   5,\n      diff: 'Hard',\n      tag:  'Integrated Rheumatology &mdash; Autoantibody Interpretation',\n      stem: 'Four patients each have a positive ANA (all at 1:160 or above, speckled pattern). Their additional antibody results and clinical features are listed. <strong>Patient 1<\/strong>: anti-dsDNA positive, anti-Sm positive; malar rash, Class IV lupus nephritis, C3\/C4 low. <strong>Patient 2<\/strong>: anti-U1-RNP positive (high titre), anti-dsDNA negative, anti-Sm negative; puffy hands, Raynaud\\'s, proximal myopathy, CK 2,400 IU\/L. <strong>Patient 3<\/strong>: anti-SSA positive, anti-SSB positive, anti-dsDNA negative; dry eyes and mouth, parotid swelling, focus score 2\/4mm&sup2; on lip biopsy. <strong>Patient 4<\/strong>: anti-Scl-70 positive, anti-centromere negative; diffuse skin thickening to the trunk, ground-glass opacities on HRCT chest. For which patient is the <em>risk of pulmonary arterial hypertension (PAH)<\/em> as the <strong>leading cause of death<\/strong> most directly predicted by the antibody profile?',\n      correct: 'Patient 2 (MCTD with anti-U1-RNP); PAH is the leading cause of death in MCTD and anti-U1-RNP positivity directly predicts PAH risk; annual echocardiography is mandatory',\n      opts: [\n        'Patient 2 (MCTD with anti-U1-RNP); PAH is the leading cause of death in MCTD and anti-U1-RNP positivity directly predicts PAH risk; annual echocardiography is mandatory',\n        'Patient 4 (diffuse SSc with anti-Scl-70); anti-Scl-70 predicts severe ILD as the leading cause of death in dcSSc, but PAH is the leading cause of death in all SSc subtypes regardless of antibody type; anti-centromere negativity excludes limited SSc where PAH risk is highest',\n        'Patient 1 (SLE with anti-dsDNA and active nephritis); Class IV lupus nephritis is the most common cause of death in SLE and low complement levels confirm active immune-complex-mediated PAH from pulmonary vasculitis',\n        'Patient 3 (Sjogren\\'s with anti-SSA\/SSB); PAH occurs in up to 20% of primary Sjogren\\'s syndrome and anti-SSB positivity is the antibody that most specifically predicts pulmonary vascular involvement in this disease'\n      ],\n      exp:  'This integrative question tests antibody-to-prognosis mapping across four CTDs. <strong>Patient 1 (SLE)<\/strong>: anti-dsDNA + anti-Sm confirm SLE. Leading cause of death: infection, renal failure, and cardiovascular disease. PAH occurs in SLE but is not the leading cause. <strong>Patient 2 (MCTD)<\/strong>: high-titre anti-U1-RNP with absent disease-specific antibodies defines MCTD. <strong>PAH is the leading cause of death in MCTD<\/strong>, occurring in 10&ndash;45% of patients. The anti-U1-RNP antibody directly drives pulmonary vascular remodelling. Annual echocardiography is mandatory. <strong>Patient 3 (Sjogren\\'s)<\/strong>: anti-SSA\/SSB with sicca symptoms and positive biopsy. Leading cause of death: lymphoma, not PAH. <strong>Patient 4 (diffuse SSc with anti-Scl-70)<\/strong>: anti-Scl-70 predicts severe, early ILD &mdash; <strong>ILD is the leading cause of death in dcSSc<\/strong> (not PAH). PAH is the leading cause of death in <em>limited<\/em> SSc (anti-centromere positive). This distinction is a recurring exam trap.',\n      extra: '<strong>Leading cause of death by CTD &mdash; the essential exam table:<\/strong><br>SLE: infection (especially during immunosuppression); cardiovascular disease (accelerated atherosclerosis); renal failure in poorly controlled LN.<br>Limited SSc (lcSSc \/ anti-centromere): <strong>pulmonary arterial hypertension (PAH)<\/strong>.<br>Diffuse SSc (dcSSc \/ anti-Scl-70): <strong>interstitial lung disease (ILD)<\/strong>; also scleroderma renal crisis in anti-RNA pol III patients.<br>MCTD (anti-U1-RNP): <strong>pulmonary arterial hypertension (PAH)<\/strong>.<br>Antisynthetase syndrome (anti-Jo-1): <strong>ILD<\/strong>.<br>EGPA: <strong>cardiac involvement<\/strong> (eosinophilic myocarditis).<br>GPA: historically renal failure; now with treatment, infection during immunosuppression.<br><strong>PAH screening in rheumatology<\/strong>: echocardiography annually in lcSSc, MCTD, and SLE with unexplained dyspnoea. Right heart catheterisation is the gold standard for diagnosis (mPAP &ge;20 mmHg at rest). Treatment: endothelin receptor antagonists (bosentan, macitentan); PDE-5 inhibitors (sildenafil, tadalafil); prostacyclin analogues (iloprost, selexipag).',\n      imgId: 'rhmq07-img1'\n    }\n\n  ];\n\n  var answers  = {};\n  var answered = 0;\n  var shuffled = {};\n  var done     = false;\n\n  function byId(id) { return document.getElementById(id); }\n  function gid(sfx) { return byId(NS + '-' + sfx); }\n\n  function shuffleArr(arr) {\n    var a = arr.slice(), i, j, t;\n    for (i = a.length - 1; i > 0; i--) {\n      j = Math.floor(Math.random() * (i + 1));\n      t = a[i]; a[i] = a[j]; a[j] = t;\n    }\n    return a;\n  }\n\n  function countVal(val) {\n    var k, n = 0;\n    for (k in answers) {\n      if (answers.hasOwnProperty(k) && answers[k] === val) n++;\n    }\n    return n;\n  }\n\n  function buildPips() {\n    var cont = gid('pips'), i, q, wl, wp, line, pip;\n    if (!cont) return;\n    cont.innerHTML = '';\n    for (i = 0; i < QS.length; i++) {\n      q = QS[i];\n      if (i > 0) {\n        wl = document.createElement('div'); wl.className = 'mr-pip-wrap';\n        line = document.createElement('div'); line.className = 'mr-pip-line';\n        line.id = NS + '-pl' + q.id;\n        wl.appendChild(line); cont.appendChild(wl);\n      }\n      wp  = document.createElement('div'); wp.className = 'mr-pip-wrap';\n      pip = document.createElement('div'); pip.className = 'mr-pip';\n      pip.id = NS + '-pip' + q.id;\n      pip.textContent = String(q.id);\n      wp.appendChild(pip); cont.appendChild(wp);\n    }\n  }\n\n  function build() {\n    var cont, i, q, opts, card, top, nd, meta, tagRow, tg, dl,\n        st, rule, od, ed, lb, tx, ep, epl, ept, imgSrc, imgDiv, j, oe, ls, ts;\n    cont = gid('cases');\n    if (!cont) return;\n    cont.innerHTML = '';\n    answers = {}; answered = 0; shuffled = {}; done = false;\n    if (gid('score')) gid('score').style.display = 'none';\n    buildPips();\n\n    for (i = 0; i < QS.length; i++) {\n      q    = QS[i];\n      opts = shuffleArr(q.opts);\n      shuffled[q.id] = opts;\n\n      card = document.createElement('div'); card.className = 'mr-case';\n      top  = document.createElement('div'); top.className  = 'mr-case-top';\n      nd   = document.createElement('div'); nd.className   = 'mr-num';\n      nd.textContent = q.id < 10 ? '0' + q.id : String(q.id);\n      meta = document.createElement('div'); meta.className = 'mr-meta';\n\n      tagRow = document.createElement('div'); tagRow.className = 'mr-tag-row';\n      tg = document.createElement('div'); tg.className = 'mr-tag'; tg.innerHTML = q.tag;\n      dl = document.createElement('div'); dl.className = 'mr-diff'; dl.textContent = q.diff;\n      tagRow.appendChild(tg); tagRow.appendChild(dl);\n\n      st = document.createElement('div'); st.className = 'mr-stem'; st.innerHTML = q.stem;\n      meta.appendChild(tagRow); meta.appendChild(st);\n      top.appendChild(nd); top.appendChild(meta);\n      card.appendChild(top);\n\n      rule = document.createElement('div'); rule.className = 'mr-rule';\n      card.appendChild(rule);\n\n      od = document.createElement('div'); od.className = 'mr-opts';\n      for (j = 0; j < opts.length; j++) {\n        oe = document.createElement('div'); oe.className = 'mr-opt';\n        oe.id = NS + '-o' + q.id + '-' + j;\n        oe.setAttribute('role', 'button'); oe.setAttribute('tabindex', '0');\n        ls = document.createElement('span'); ls.className = 'mr-ltr'; ls.textContent = LTRS[j];\n        ts = document.createElement('span'); ts.className = 'mr-opt-text'; ts.innerHTML = opts[j];\n        oe.appendChild(ls); oe.appendChild(ts); od.appendChild(oe);\n        (function (qid, oi) {\n          oe.addEventListener('click', function () { pick(qid, oi); });\n        }(q.id, j));\n      }\n      card.appendChild(od);\n\n      ed  = document.createElement('div'); ed.className = 'mr-exp'; ed.id = NS + '-exp' + q.id;\n      lb  = document.createElement('div'); lb.className = 'mr-exp-lbl'; lb.textContent = 'Debrief';\n      tx  = document.createElement('div'); tx.className = 'mr-exp-text'; tx.innerHTML = q.exp;\n      ed.appendChild(lb); ed.appendChild(tx);\n\n      if (q.imgId) {\n        imgSrc = byId(q.imgId);\n        if (imgSrc) {\n          imgDiv = document.createElement('div');\n          imgDiv.innerHTML = imgSrc.innerHTML;\n          ed.appendChild(imgDiv);\n        }\n      }\n\n      if (q.extra) {\n        ep  = document.createElement('div'); ep.className = 'mr-exp-extra';\n        epl = document.createElement('span'); epl.className = 'mr-exp-extra-lbl'; epl.textContent = 'Extra Points';\n        ept = document.createElement('div'); ept.innerHTML = q.extra;\n        ep.appendChild(epl); ep.appendChild(ept);\n        ed.appendChild(ep);\n      }\n\n      card.appendChild(ed);\n      cont.appendChild(card);\n    }\n  }\n\n  function pick(qid, oi) {\n    var q, opts, i, el, ok;\n    if (answers[qid] !== undefined || done) return;\n    q = null;\n    for (i = 0; i < QS.length; i++) { if (QS[i].id === qid) { q = QS[i]; break; } }\n    if (!q) return;\n    opts = shuffled[qid];\n    ok   = (opts[oi] === q.correct);\n    answers[qid] = ok ? 'c' : 'w';\n    answered++;\n    for (i = 0; i < opts.length; i++) {\n      el = byId(NS + '-o' + qid + '-' + i);\n      if (!el) continue;\n      el.className = opts[i] === q.correct ? 'mr-opt correct locked'\n                   : i === oi              ? 'mr-opt wrong locked'\n                                           : 'mr-opt dimmed locked';\n    }\n    var ex = byId(NS + '-exp' + qid); if (ex) ex.style.display = 'block';\n    var pp = byId(NS + '-pip' + qid); if (pp) pp.className = 'mr-pip ' + (ok ? 'correct' : 'wrong');\n    if (qid > 1) { var pl = gid('pl' + qid); if (pl) pl.className = 'mr-pip-line done'; }\n  }\n\n  function showScore() {\n    var c, w, s, net, pct, disp, vlist, vi, sc;\n    if (done) return;\n    done = true;\n    c   = countVal('c'); w = countVal('w'); s = TOTAL - answered;\n    net  = c * 4 - w;\n    pct  = Math.max(0, Math.round((net \/ MAX) * 100));\n    disp = Math.min(100, Math.max(0, pct));\n    var rg = gid('ring');\n    if (rg) rg.style.background = 'conic-gradient(#8B3D20 ' + disp + '%, #E8DDD8 0%)';\n    var pe = gid('pct'); if (pe) pe.textContent = pct + '%';\n    var ne = gid('net'); if (ne) ne.textContent = 'Net Score: ' + net + ' \/ ' + MAX;\n    vlist = [\n      [5, 'Flawless. The full rheumatology spectrum \\u2014 you command it.'],\n      [4, 'Strong \\u2014 one cross-cutting nuance worth a final read.'],\n      [3, 'Solid \\u2014 the pharmacology traps and PAH table are the marks that separate candidates.'],\n      [2, 'Halfway \\u2014 the leading-cause-of-death table and MTX pneumonitis repay close study.'],\n      [0, 'This series has given you everything. Read the Summary file, then come back to this round \\u2014 the pattern will be clear.']\n    ];\n    var ve = gid('verdict');\n    if (ve) {\n      ve.textContent = vlist[4][1];\n      for (vi = 0; vi < vlist.length; vi++) {\n        if (c >= vlist[vi][0]) { ve.textContent = vlist[vi][1]; break; }\n      }\n    }\n    var cc = gid('ct-c'); if (cc) cc.textContent = '\\u2705 ' + c + ' Correct';\n    var cw = gid('ct-w'); if (cw) cw.textContent = '\\u274C ' + w + ' Wrong';\n    var cs = gid('ct-s'); if (cs) cs.textContent = '\\u23ED ' + s + ' Skipped';\n    sc = gid('score');\n    if (sc) { sc.style.display = 'block'; sc.scrollIntoView({ behavior: 'smooth', block: 'center' }); }\n  }\n\n  function initObserver() {\n    var sn = gid('sentinel'), bar = gid('progress');\n    if (!sn || !bar || !window.IntersectionObserver) return;\n    new IntersectionObserver(function (en) {\n      bar.className = en[0].isIntersecting ? 'mr-progress' : 'mr-progress visible';\n    }, { threshold: 0 }).observe(sn);\n  }\n\n  function init() {\n    var sb = gid('submit'), rb = gid('retry');\n    if (!sb || !rb) return;\n    sb.addEventListener('click', showScore);\n    rb.addEventListener('click', function () { build(); window.scrollTo(0, 0); });\n    initObserver();\n    build();\n  }\n\n  function tryInit(n) {\n    if (document.getElementById('rhmq07-cases')) {\n      init();\n    } else if (n < 40) {\n      setTimeout(function () { tryInit(n + 1); }, 50);\n    }\n  }\n\n  tryInit(0);\n\n}());\n<\/script>\n\n\n","protected":false},"excerpt":{"rendered":"<p>Morning Rounds \u00b7 Rheumatology Mixed High-Yield Round Antibody Disease Key Point Anti-dsDNA SLE (specific) Titres track disease activity Anti-Sm SLE (most specific) Does not track activity Anti-histone Drug-induced lupus Anti-dsDNA absent in DIL Anti-SSA (Ro) Sjogren's; SLE Neonatal lupus; CHB Anti-SSB (La) Sjogren's (more specific) Usually with anti-SSA Anti-centromere Limited SSc (CREST) PAH; late ILD&hellip;&nbsp;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[74,24,64],"tags":[],"class_list":["post-36958","post","type-post","status-publish","format-standard","hentry","category-morning-rounds","category-neet-pg","category-orthopaedics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rheumatology Series: Mixed High-Yield Round - atsixty<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-mixed-high-yield\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rheumatology Series: Mixed High-Yield Round - atsixty\" \/>\n<meta property=\"og:description\" content=\"Morning Rounds \u00b7 Rheumatology Mixed High-Yield Round Antibody Disease Key Point Anti-dsDNA SLE (specific) Titres track disease activity Anti-Sm SLE (most specific) Does not track activity Anti-histone Drug-induced lupus Anti-dsDNA absent in DIL Anti-SSA (Ro) Sjogren&#039;s; SLE Neonatal lupus; CHB Anti-SSB (La) Sjogren&#039;s (more specific) Usually with anti-SSA Anti-centromere Limited SSc (CREST) PAH; late ILD&hellip;&nbsp;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-mixed-high-yield\/\" \/>\n<meta property=\"og:site_name\" content=\"atsixty\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-06T03:45:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-06T04:27:34+00:00\" \/>\n<meta name=\"author\" content=\"Avi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Avi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/rheumatology-mixed-high-yield\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/rheumatology-mixed-high-yield\\\/\"},\"author\":{\"name\":\"Avi\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"headline\":\"Rheumatology Series: Mixed High-Yield Round\",\"datePublished\":\"2026-06-06T03:45:20+00:00\",\"dateModified\":\"2026-06-06T04:27:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/rheumatology-mixed-high-yield\\\/\"},\"wordCount\":171,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"articleSection\":[\"Morning Rounds\",\"NEET PG\",\"Orthopaedics\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/rheumatology-mixed-high-yield\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/rheumatology-mixed-high-yield\\\/\",\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/rheumatology-mixed-high-yield\\\/\",\"name\":\"Rheumatology Series: Mixed High-Yield Round - atsixty\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\"},\"datePublished\":\"2026-06-06T03:45:20+00:00\",\"dateModified\":\"2026-06-06T04:27:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/rheumatology-mixed-high-yield\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/rheumatology-mixed-high-yield\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/rheumatology-mixed-high-yield\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/atsixty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rheumatology Series: Mixed High-Yield Round\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\",\"url\":\"https:\\\/\\\/atsixty.com\\\/\",\"name\":\"At Sixty\",\"description\":\"The Option Taken\",\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atsixty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\",\"name\":\"Avi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"url\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"contentUrl\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"width\":200,\"height\":200,\"caption\":\"Avi\"},\"logo\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\"},\"sameAs\":[\"https:\\\/\\\/atsixty.com\"],\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/author\\\/avinaux\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rheumatology Series: Mixed High-Yield Round - atsixty","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-mixed-high-yield\/","og_locale":"en_US","og_type":"article","og_title":"Rheumatology Series: Mixed High-Yield Round - atsixty","og_description":"Morning Rounds \u00b7 Rheumatology Mixed High-Yield Round Antibody Disease Key Point Anti-dsDNA SLE (specific) Titres track disease activity Anti-Sm SLE (most specific) Does not track activity Anti-histone Drug-induced lupus Anti-dsDNA absent in DIL Anti-SSA (Ro) Sjogren's; SLE Neonatal lupus; CHB Anti-SSB (La) Sjogren's (more specific) Usually with anti-SSA Anti-centromere Limited SSc (CREST) PAH; late ILD&hellip;&nbsp;","og_url":"https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-mixed-high-yield\/","og_site_name":"atsixty","article_published_time":"2026-06-06T03:45:20+00:00","article_modified_time":"2026-06-06T04:27:34+00:00","author":"Avi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Avi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-mixed-high-yield\/#article","isPartOf":{"@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-mixed-high-yield\/"},"author":{"name":"Avi","@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"headline":"Rheumatology Series: Mixed High-Yield Round","datePublished":"2026-06-06T03:45:20+00:00","dateModified":"2026-06-06T04:27:34+00:00","mainEntityOfPage":{"@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-mixed-high-yield\/"},"wordCount":171,"commentCount":0,"publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"articleSection":["Morning Rounds","NEET PG","Orthopaedics"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-mixed-high-yield\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-mixed-high-yield\/","url":"https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-mixed-high-yield\/","name":"Rheumatology Series: Mixed High-Yield Round - atsixty","isPartOf":{"@id":"https:\/\/atsixty.com\/#website"},"datePublished":"2026-06-06T03:45:20+00:00","dateModified":"2026-06-06T04:27:34+00:00","breadcrumb":{"@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-mixed-high-yield\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-mixed-high-yield\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/rheumatology-mixed-high-yield\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/atsixty.com\/"},{"@type":"ListItem","position":2,"name":"Rheumatology Series: Mixed High-Yield Round"}]},{"@type":"WebSite","@id":"https:\/\/atsixty.com\/#website","url":"https:\/\/atsixty.com\/","name":"At Sixty","description":"The Option Taken","publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atsixty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d","name":"Avi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","url":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","contentUrl":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","width":200,"height":200,"caption":"Avi"},"logo":{"@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png"},"sameAs":["https:\/\/atsixty.com"],"url":"https:\/\/atsixty.com\/index.php\/author\/avinaux\/"}]}},"_links":{"self":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36958","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/comments?post=36958"}],"version-history":[{"count":1,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36958\/revisions"}],"predecessor-version":[{"id":36959,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36958\/revisions\/36959"}],"wp:attachment":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/media?parent=36958"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/categories?post=36958"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/tags?post=36958"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}